Adherence to Positive Airway Pressure Therapy in a Cohort of Colombian Patients with Obstructive Sleep Apnea Syndrome

Judith L Ortiz; Diego Rosselli

doi:10.1055/s-0043-1770799

Adherence to Positive Airway Pressure Therapy in a Cohort of Colombian Patients with Obstructive Sleep Apnea Syndrome

Sleep Sci. 2023 Jul 6;16(2):227-230. doi: 10.1055/s-0043-1770799. eCollection 2023 Jun.

Authors

Judith L Ortiz¹, Diego Rosselli²

Affiliations

¹ Faculty of Economic and Administrative Sciences, Pontificia Universidad Javeriana, Bogota, DC, Colombia.
² Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, DC, Colombia.

Abstract

Objective To describe the adherence to the use of positive air pressure (PAP) devices in a cohort of patients with sleep apnea syndrome in Colombia. Material and Methods Descriptive cross-sectional study of adult patients treated between January 2018 and December 2019 in the sleep clinic of a private insurer in Colombia. Results The analysis included 12,538 patients (51.3% women) with a mean age of 61.3 years; 10,220 patients (81.5%) use CPAP and 1,550 (12.4%) BIPAP. Only 37% are adherent (> 70% of use for 4 hours or more), adherence rates were highest in the >65 years age groups. 2,305 patients (18.5%) were hospitalized, on average 3.2 times; 515 of these (21.3%) had one or more cardiovascular comorbidities. Conclusion Adherence rates in this sample are lower than those reported elsewhere. They are similar in males and females and tend to improve with age.

Keywords: Cardiovascular diseases; Continuous Positive Airway Pressure; Obstructive; Sleep Apnea; Treatment Adherence and Compliance.

Brazilian Sleep Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).